Diabetes Type I

Clinical studies are evaluating Mesenchymal Stem Cells (MSCs) in Type 1 diabetes, focusing on how they may influence immune pathways and help preserve pancreatic function. 

Type 1 diabetes is an autoimmune disease in which glutamic acid decarboxylase (GAD) is a major auto-antigen targeted by the immune system and thereby  destroys insulin-producing beta cells in the pancreas. This leads to insulin deficiency, high blood sugar and death if untreated. Even if adedquately treated long-term complications often arise affecting multiple organ-systems of the body being an important contributor to morbidity. MSC trials are still early and primarily exploratory, but they are contributing to the broader field of autoimmune and metabolic disease research. 

Clinical Trials

One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study — Jing Lu, et al.


 

Allogenic Adipose Tissue-Derived Stromal/Stem Cells and Vitamin D Supplementation in Patients With Recent-Onset Type 1 Diabetes Mellitus: A 3-Month Follow-Up Pilot Study — Debora B Araujo, et al.


 

Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial — Mahmoud Izadi, et al.